Literature DB >> 22540203

Opioids should not be used in migraine.

Stewart J Tepper1.   

Abstract

Opioids should not be used for the treatment of migraine. This brief review explores why not. Alternative acute and preventive agents should always be explored. Opioids do not work well clinically in migraine. No randomized controlled study shows pain-free results with opioids in the treatment of migraine. Saper and colleagues' 5-year study showed minimal effectiveness, with many contract violations, interfering with the therapeutic alliance. The physiologic consequences of opioid use are adverse, occur quickly, and can be permanent. Decreased gray matter, release of calcitonin gene-related peptide, dynorphin, and pro-inflammatory peptides, and activation of excitatory glutamate receptors are all associated with opioid exposure. Opioids are pro-nociceptive, prevent reversal of migraine central sensitization, and interfere with triptan effectiveness. Opioids precipitate bad clinical outcomes, especially transformation to daily headache. They cause disease progression, comorbidity, and excessive health care consumption. Use of opioids in migraine is pennywise and pound foolish.
© 2012 American Headache Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22540203     DOI: 10.1111/j.1526-4610.2012.02140.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  13 in total

1.  [The role of opioids in the treatment of primary headache disorders].

Authors:  A Totzeck; C Gaul
Journal:  Schmerz       Date:  2014-04       Impact factor: 1.107

Review 2.  When indomethacin fails: additional treatment options for "indomethacin responsive headaches".

Authors:  Shuhan Zhu; Brian McGeeney
Journal:  Curr Pain Headache Rep       Date:  2015-03

3.  NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in mice.

Authors:  Katarzyna M Targowska-Duda; Akihiko Ozawa; Zachariah Bertels; Andrea Cippitelli; Jason L Marcus; Hanna K Mielke-Maday; Gilles Zribi; Amanda N Rainey; Brigitte L Kieffer; Amynah A Pradhan; Lawrence Toll
Journal:  Neuropharmacology       Date:  2020-03-06       Impact factor: 5.250

4.  Medication overuse headache following repeated morphine, but not [INCREMENT]9-tetrahydrocannabinol administration in the female rat.

Authors:  Ram Kandasamy; Cole T Dawson; Tammy N Hilgendorf; Michael M Morgan
Journal:  Behav Pharmacol       Date:  2018-08       Impact factor: 2.293

5.  Assessing evidence-based medicine and opioid/barbiturate as first-line acute treatment of pediatric migraine and primary headache: A retrospective observational study of health systems data.

Authors:  Elizabeth K Seng; Amy A Gelfand; Robert A Nicholson
Journal:  Cephalalgia       Date:  2019-02-20       Impact factor: 6.292

6.  Opioid Prescriptions for Acute and Chronic Pain Management Among Medicaid Beneficiaries.

Authors:  Chandrashekar Janakiram; Paul Fontelo; Vojtech Huser; Natalia I Chalmers; Gabriela Lopez Mitnik; Avery R Brow; Timothy J Iafolla; Bruce A Dye
Journal:  Am J Prev Med       Date:  2019-08-01       Impact factor: 5.043

7.  An Examination of Comorbid Generalized Anxiety Disorder and Chronic Pain on Substance Misuse in a Canadian Population-Based Survey.

Authors:  Elena Bilevicius; Jordana L Sommer; Matthew T Keough; Renée El-Gabalawy
Journal:  Can J Psychiatry       Date:  2020-01-03       Impact factor: 4.356

8.  Navigating migraine care through the COVID-19 pandemic: an update.

Authors:  Heather Angus-Leppan; Angelica E Guiloff; Karen Benson; Roberto J Guiloff
Journal:  J Neurol       Date:  2021-05-17       Impact factor: 4.849

9.  Pharmacotherapeutics knowledge of some nonemergency and emergency conditions among medical undergraduates in an Indian medical college.

Authors:  Sarfaraz Alam Khan; Nazeem Ishrat Siddiqui
Journal:  Indian J Pharmacol       Date:  2016 May-Jun       Impact factor: 1.200

10.  Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study.

Authors:  Sachin V Pasricha; Mina Tadrous; Wayne Khuu; David N Juurlink; Muhammad M Mamdani; J Michael Paterson; Tara Gomes
Journal:  Pain       Date:  2018-08       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.